DIPYRIDAMOLE ADMINISTERED INTRAVENOUSLY: 50 mg.
AMINOPHYLLINE ADMINISTERED INTRAVENOUSLY: 150 mg.
VITAL SIGNS: Pre-dipyridamole: 73 bpm. BP: 126/80 mmHg.
Post-dipyridamole: 68 bpm. BP: 118/68 mmHg.
ECG: Resting: Normal sinus rhythm. Normal ECG.
Dipyridamole: No significant ST segment depression. No chest pain. No ahythmia.
TECHNICAL FACTORS: Good quality gated tomographic myocardial perfusion images acquired in supine position following dipyridamole stress and at rest using CZT camera without attenuation correction. Stress imaging was also acquired in prone position. Technetium-99m tetrofosmin was administered intravenously at rest 249 MBq and at peak stress 611 MBq. Height: 173 cm. Weight: 89 kg. Half dose protocols used to acquire rest and stress images.
Hemodynamic response to dipyridamole: No.
Artifacts: Diaphragmatic attenuation artifact.
LV FUNCTION:
REST: Ejection fraction 61%, LVEDV (ml): 145, LVESV (ml): 57
STRESS: Ejection fraction 55%, LVEDV (ml): 148, LVESV (ml): 66
POST STRESS (PRONE): Ejection fraction 58%, LVEDV (ml): 137, LVESV (ml): 57
TID Ratio: 1.08 (Normal <1.2)
OPINION:
1. Normal study. Half radiation dose protocol used.
2. DIPYRIDAMOLE ECG: Negative stress ECG for ischemia by ST segment criteria. No chest pain. No arrhythmia.
3. MYOCARDIAL PERFUSION: Normal perfusion at rest and following stress.
4. LV FUNCTION- REST: Normal LV size, ejection fraction and wall motion.
STRESS: No significant change compared to rest imaging.
POST-STRESS (Prone):No significant change compared to post-stress (supine) imaging.
5. Myocardial flow reserve. MFR =2.7
6. No prior study for comparison.
